• Mon news: AZ obesity pill. 50% of drug shortages last at least 2 years. Pharmas and IRA lawsuit appeals. Novo-Ascendis biobucks deal. Wegovy reduces all-cause hospital admissions. See more on our front page

Bye bye Sumitomo

Quote




A reorg will give the incompetent leadership team a sense of purpose. They don’t bring any other value so following a script of directives is all they’re capable of doing.
 








anonymous said:
Any time now- there is no way they can be profitable in 2024 and they have to be profitable in 2024.
Click to expand...

If they are holding to their 2024 financial projections from their May 2023 mid-term business plan, that was before Ulotaront failed and the quarter-to-quarter growth rate of the Vant drugs seemingly collapsed with the last 2 publicly reported quarters. I can’t see how they don’t make some staff cuts among many other types of cost cutting moves.

Many co-workers who I speak to that would classify as the true all-star performer types we need are hoping and praying to get cut. They are all severely burnt out and at a breaking point. If they don’t get the severance or an option to volunteer to take a package, some plan to quit very soon.

Some areas where work was handled by a combined 15-20 employees previously across all the separate US companies is now handled by a team of 5-8 sometimes fewer…and of the 5-8 remaining some of that staff is inexperienced and can’t contribute much for their group or some are there to check a box or a few boxes and they don’t do much either and know they can get away with it.

…so it all amounts to maybe 2 employees in a group doing the real meaningful day-to-day functional work covering all of SMPA which was previously handled by 15-20 and was previously 5 separate and distinct companies. Look at any group across the company that does any sort of key operational activity that you all take for granted and you’ll notice it’s now like 2 employees and a bunch of duct tape barely keeping things together the last 7 months. God help SMPA if they leave or drop-dead from a heart attack or stroke.
 




anonymous said:
If they are holding to their 2024 financial projections from their May 2023 mid-term business plan, that was before Ulotaront failed and the quarter-to-quarter growth rate of the Vant drugs seemingly collapsed with the last 2 publicly reported quarters. I can’t see how they don’t make some staff cuts among many other types of cost cutting moves.

Many co-workers who I speak to that would classify as the true all-star performer types we need are hoping and praying to get cut. They are all severely burnt out and at a breaking point. If they don’t get the severance or an option to volunteer to take a package, some plan to quit very soon.

Some areas where work was handled by a combined 15-20 employees previously across all the separate US companies is now handled by a team of 5-8 sometimes fewer…and of the 5-8 remaining some of that staff is inexperienced and can’t contribute much for their group or some are there to check a box or a few boxes and they don’t do much either and know they can get away with it.

…so it all amounts to maybe 2 employees in a group doing the real meaningful day-to-day functional work covering all of SMPA which was previously handled by 15-20 and was previously 5 separate and distinct companies. Look at any group across the company that does any sort of key operational activity that you all take for granted and you’ll notice it’s now like 2 employees and a bunch of duct tape barely keeping things together the last 7 months. God help SMPA if they leave or drop-dead from a heart attack or stroke.
Click to expand...


So you’re saying you’re short staffed? According to the upcoming rebalancing act, smpa is going to become leaner. There’s too many departments doing the same thing but still doing it on their own. Once the migration is complete a lot of those arms will become one with quite a few people cut. Be careful what you wish for because you may just all get rebalanced out of a job.
 
































































Top Bottom
Back
Quote